Positive News SentimentPositive NewsNASDAQ:BWAY Brainsway (BWAY) Stock Price, News & Analysis $11.83 -0.01 (-0.08%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.95 +0.12 (+1.01%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Brainsway Stock (NASDAQ:BWAY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Brainsway alerts:Sign Up Key Stats Today's Range$11.63▼$12.0050-Day Range$10.19▼$13.3752-Week Range$6.61▼$13.65Volume59,082 shsAverage Volume45,799 shsMarket Capitalization$223.59 millionP/E Ratio59.15Dividend YieldN/APrice Target$14.25Consensus RatingBuy Company Overview BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Read More Brainsway Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreBWAY MarketRank™: Brainsway scored higher than 65% of companies evaluated by MarketBeat, and ranked 366th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingBrainsway has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBrainsway has only been the subject of 1 research reports in the past 90 days.Read more about Brainsway's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth100.00% Earnings GrowthEarnings for Brainsway are expected to grow by 100.00% in the coming year, from $0.08 to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Brainsway is 59.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Brainsway is 59.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.89.Price to Book Value per Share RatioBrainsway has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Brainsway's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.58% of the outstanding shares of Brainsway have been sold short.Short Interest Ratio / Days to CoverBrainsway has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainsway has recently decreased by 11.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBrainsway does not currently pay a dividend.Dividend GrowthBrainsway does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.58% of the outstanding shares of Brainsway have been sold short.Short Interest Ratio / Days to CoverBrainsway has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Brainsway has recently decreased by 11.72%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News SentimentN/A News SentimentBrainsway has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.Search Interest1 people have searched for BWAY on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Brainsway to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Brainsway insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of Brainsway is held by institutions.Read more about Brainsway's insider trading history. Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainsway and its competitors with MarketBeat's FREE daily newsletter. Email Address BWAY Stock News HeadlinesBrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health ProfessionalsJuly 31, 2025 | finance.yahoo.comStrength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? - NasdaqJune 26, 2025 | nasdaq.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.August 8 at 2:00 AM | Brownstone Research (Ad)Wall Street Analysts Believe Brainsway (BWAY) Could Rally 30.98%: Here's is How to Trade - NasdaqJune 26, 2025 | nasdaq.comBrainsway Ltd. ADRJune 19, 2025 | marketwatch.comBrainsWay reports promising results for accelerated depression treatmentJune 12, 2025 | investing.comBrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)June 11, 2025 | globenewswire.comBrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San DiegoJune 10, 2025 | globenewswire.comSee More Headlines BWAY Stock Analysis - Frequently Asked Questions How have BWAY shares performed this year? Brainsway's stock was trading at $9.43 at the beginning of the year. Since then, BWAY stock has increased by 25.5% and is now trading at $11.83. How were Brainsway's earnings last quarter? Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) issued its earnings results on Tuesday, May, 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The company earned $11.54 million during the quarter, compared to analyst estimates of $11.45 million. Brainsway had a trailing twelve-month return on equity of 7.35% and a net margin of 9.01%. Read the conference call transcript. When did Brainsway IPO? Brainsway (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO. Who are Brainsway's major shareholders? Brainsway's top institutional investors include Phoenix Financial Ltd. (1.92%), Acadian Asset Management LLC (1.77%), ARK Investment Management LLC (1.06%) and Huntleigh Advisors Inc. (0.41%). How do I buy shares of Brainsway? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainsway own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP). Company Calendar Last Earnings5/13/2025Today8/07/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BWAY CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Brainsway$14.25 High Price Target$16.00 Low Price Target$12.50 Potential Upside/Downside+20.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.20 Trailing P/E Ratio59.15 Forward P/E Ratio147.88 P/E GrowthN/ANet Income$2.92 million Net Margins9.01% Pretax Margin10.22% Return on Equity7.35% Return on Assets4.72% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio4.75 Sales & Book Value Annual Sales$41.02 million Price / Sales5.45 Cash Flow$0.25 per share Price / Cash Flow47.48 Book Value$3.31 per share Price / Book3.57Miscellaneous Outstanding Shares18,900,000Free Float15,307,000Market Cap$223.59 million OptionableNot Optionable Beta1.42 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:BWAY) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainsway Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainsway With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.